Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M E Schmidt

Showing results (41-50 of 68) with videos related to

Pageof 7
Sort By:
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|April 1, 1997
Gender differences in brain metabolic and plasma catecholamine responses to alpha 2-adrenoceptor blockadeM E Schmidt, J A Matochik, D S Goldstein, et al.
Biochemical Genetics|April 1, 1985
Clinal genetic variation at enzyme loci in bald eagles (Haliaeetus leucocephalus) from the western United StatesD C Morizot, R G Anthony, T G Grubb, et al.
Journal of the American Society of Nephrology : JASN|November 30, 1999
Direct correlation between hyperoxaluria/oxalate stone disease and the absence of the gastrointestinal tract-dwelling bacterium Oxalobacter formigenes: possible prevention by gut recolonization or enzyme replacement therapyH Sidhu, M E Schmidt, J G Cornelius, et al.
Psychopharmacology|October 20, 1999
Cerebral glucose metabolic and plasma catecholamine responses to the alpha(2) adrenoceptor antagonist ethoxyidazoxan given to healthy volunteersM E Schmidt, R J Oshinsky, H G Kim, et al.
Neurorx : the Journal of the American Society for Experimental Neurotherapeutics|February 21, 2006
Central nervous system drug development: an integrative biomarker approach toward individualized medicineB Gomez-Mancilla, E Marrer, J Kehren, et al.
Psychopharmacology Bulletin|January 1, 1997
Acute alpha 2 blockade by idazoxan increases insulin and lowers plasma glucose during positron emission tomographyM E Schmidt, D S Goldstein, J L Schouten, et al.
Brain, Behavior, and Immunity|May 16, 2018
Validation of inflammatory genetic variants associated with long-term cancer related fatigue in a large breast cancer cohortT Kühl, S Behrens, A Y Jung, et al.
European Journal of Medical Research|May 22, 2007
Prostate cancer tissue is masked by bicalutamide: a case reportJ Ellinger, P J Bastian, K Biermann, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 1, 1996
Cerebral glucose metabolism during pharmacologic studies: test-retest under placebo conditionsM E Schmidt, M Ernst, J A Matochik, et al.
Clinical Pharmacology and Therapeutics|June 1, 1995
Regional brain glucose metabolism after acute alpha 2-blockade by idazoxanM E Schmidt, J A Matochik, R C Risinger, et al.
Pageof 7

Showing results (41-50 of 68) with videos related to

Sort By:
Pageof 7
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|April 1, 1997
Gender differences in brain metabolic and plasma catecholamine responses to alpha 2-adrenoceptor blockadeM E Schmidt, J A Matochik, D S Goldstein, et al.
Biochemical Genetics|April 1, 1985
Clinal genetic variation at enzyme loci in bald eagles (Haliaeetus leucocephalus) from the western United StatesD C Morizot, R G Anthony, T G Grubb, et al.
Journal of the American Society of Nephrology : JASN|November 30, 1999
Direct correlation between hyperoxaluria/oxalate stone disease and the absence of the gastrointestinal tract-dwelling bacterium Oxalobacter formigenes: possible prevention by gut recolonization or enzyme replacement therapyH Sidhu, M E Schmidt, J G Cornelius, et al.
Psychopharmacology|October 20, 1999
Cerebral glucose metabolic and plasma catecholamine responses to the alpha(2) adrenoceptor antagonist ethoxyidazoxan given to healthy volunteersM E Schmidt, R J Oshinsky, H G Kim, et al.
Neurorx : the Journal of the American Society for Experimental Neurotherapeutics|February 21, 2006
Central nervous system drug development: an integrative biomarker approach toward individualized medicineB Gomez-Mancilla, E Marrer, J Kehren, et al.
Psychopharmacology Bulletin|January 1, 1997
Acute alpha 2 blockade by idazoxan increases insulin and lowers plasma glucose during positron emission tomographyM E Schmidt, D S Goldstein, J L Schouten, et al.
Brain, Behavior, and Immunity|May 16, 2018
Validation of inflammatory genetic variants associated with long-term cancer related fatigue in a large breast cancer cohortT Kühl, S Behrens, A Y Jung, et al.
European Journal of Medical Research|May 22, 2007
Prostate cancer tissue is masked by bicalutamide: a case reportJ Ellinger, P J Bastian, K Biermann, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 1, 1996
Cerebral glucose metabolism during pharmacologic studies: test-retest under placebo conditionsM E Schmidt, M Ernst, J A Matochik, et al.
Clinical Pharmacology and Therapeutics|June 1, 1995
Regional brain glucose metabolism after acute alpha 2-blockade by idazoxanM E Schmidt, J A Matochik, R C Risinger, et al.
Pageof 7